{"id":489,"date":"2015-05-20T23:26:12","date_gmt":"2015-05-20T23:26:12","guid":{"rendered":"http:\/\/depts.washington.edu\/cfrtc\/?page_id=489"},"modified":"2021-12-14T12:03:59","modified_gmt":"2021-12-14T20:03:59","slug":"current-pilots","status":"publish","type":"page","link":"https:\/\/depts.washington.edu\/cfrtc\/current-pilots\/","title":{"rendered":"Current Pilots"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” column_structure=”1_4,3_4″][et_pb_column type=”1_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_sidebar area=”et_pb_widget_area_10″ admin_label=”Pilots Sidebar” _builder_version=”4.14.2″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_sidebar][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Text” _builder_version=”3.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n

Current Pilots<\/h1>\n

\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Funding Source<\/th>Principal Investigator
\nDepartment<\/th>		Funding Period<\/th>Project Title<\/th>\n<\/tr>\n<\/thead>\n
NIH P30 CFRTC<\/td>Sid Venkatesh, PhD<\/a>
\nISB and Microbiology<\/td>		2025-26<\/td>Microbiome-targeted Diets for Rectifying GI Dysfunction in People with Cystic Fibrosis<\/a><\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>Anne Manicone, MD<\/a>
\nMedicine, Pulmonary<\/td>		2024-26<\/td>Identifying Novel Compounds to Polarize Macrophages toward Reparative States<\/a><\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>Vincenzo Cirulli, PhD<\/a>
\nMedicine, Metabolism<\/td>		2024-26<\/td>Derivation of Functional Islet Tissue from CF Patient-derived iPSC<\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Jim Bruce, PhD<\/a>
\nGenome Sciences<\/td>		2024-26<\/td>Investigation of the diagnostic potential of P. aeruginosa<\/em> protein levels in blood and urine<\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Dustin Long, MD<\/a>
\nAnesthesiology<\/td>		2024-26<\/td>Diagnostic Utility of mRNA for Characterizing Heteroresistant P. aeruginosa<\/em> Population Response to Antibiotic Treatment<\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Tom Hawn, MD, PhD<\/a>
\nAllergy & Infectios Dis<\/td>		2024-25<\/td>Non-tuberculous Mycobacteria & Cystic Fibrosis<\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>Patrick Mitchell, PhD<\/a>
\nMicrobiology<\/td>		2022-25<\/td>CFTR deficiency modulates epithelial inflammasomes<\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>Jarrad Scarlett, MD, PhD<\/a>, Peds Gastroenterology<\/td>2022-25<\/td>Role of dysfunctional gut-brain signaling in the pathogenesis of cystic fibrosis-related diabetes<\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>William Grady, MD<\/a>
\nNeel Dey, MD<\/a>
\nGastroenterology<\/td>		2022-25<\/td>Colonic inflammation and dysbiosis: Factors that induce colorectal cancer (CRC) in cystic fibrosis <\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Alison Feder, PhD<\/a>
\nGenome Sciences<\/td>		2022-25<\/td>Evolutionary and mutational drivers of P. aeruginosa<\/em> persistence through Trikafta<\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Waleed Abuzeid, MD<\/a>
\nOtolaryngology<\/td>		2020-25<\/td>Disruption of P. aeruginosa<\/em> biofilms using a novel nitric oxide-releasing nanoparticle<\/a><\/td>\n<\/tr>\n
NH P30 CFRTC<\/td>Edward Kelly, PhD<\/a>
\nPharmaceutics
\n<\/td>		2020-25<\/td>CF kidney phenotype and potential consequences in the era of CFTR correction<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Current Pilots \n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Funding Source<\/th>Principal Investigator
\nDepartment<\/th>		Funding Period<\/th>Project Title<\/th>\n<\/tr>\n<\/thead>\n
NIH P30 CFRTC<\/td>Sid Venkatesh, PhD<\/a>
\nISB and Microbiology<\/td>		2025-26<\/td>Microbiome-targeted Diets for Rectifying GI Dysfunction in People with Cystic Fibrosis<\/a><\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>Anne Manicone, MD<\/a>
\nMedicine, Pulmonary<\/td>		2024-26<\/td>Identifying Novel Compounds to Polarize Macrophages toward Reparative States<\/a><\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>Vincenzo Cirulli, PhD<\/a>
\nMedicine, Metabolism<\/td>		2024-26<\/td>Derivation of Functional Islet Tissue from CF Patient-derived iPSC<\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Jim Bruce, PhD<\/a>
\nGenome Sciences<\/td>		2024-26<\/td>Investigation of the diagnostic potential of P. aeruginosa<\/em> protein levels in blood and urine<\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Dustin Long, MD<\/a>
\nAnesthesiology<\/td>		2024-26<\/td>Diagnostic Utility of mRNA for Characterizing Heteroresistant P. aeruginosa<\/em> Population Response to Antibiotic Treatment<\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Tom Hawn, MD, PhD<\/a>
\nAllergy & Infectios Dis<\/td>		2024-25<\/td>Non-tuberculous Mycobacteria & Cystic Fibrosis<\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>Patrick Mitchell, PhD<\/a>
\nMicrobiology<\/td>		2022-25<\/td>CFTR deficiency modulates epithelial inflammasomes<\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>Jarrad Scarlett, MD, PhD<\/a>, Peds Gastroenterology<\/td>2022-25<\/td>Role of dysfunctional gut-brain signaling in the pathogenesis of cystic fibrosis-related diabetes<\/td>\n<\/tr>\n
NIH P30 CFRTC<\/td>William Grady, MD<\/a>
\nNeel Dey, MD<\/a>
\nGastroenterology<\/td>		2022-25<\/td>Colonic inflammation and dysbiosis: Factors that induce colorectal cancer (CRC) in cystic fibrosis <\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Alison Feder, PhD<\/a>
\nGenome Sciences<\/td>		2022-25<\/td>Evolutionary and mutational drivers of P. aeruginosa<\/em> persistence through Trikafta<\/a><\/td>\n<\/tr>\n
CFF RDP<\/td>Waleed Abuzeid, MD<\/a>
\nOtolaryngology<\/td>		2020-25<\/td>Disruption of P. aeruginosa<\/em> biofilms using a novel nitric oxide-releasing nanoparticle<\/a><\/td>\n<\/tr>\n
NH P30 CFRTC<\/td>Edward Kelly, PhD<\/a>
\nPharmaceutics
\n<\/td>		2020-25<\/td>CF kidney phenotype and potential consequences in the era of CFTR correction<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"open","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/cfrtc\/wp-json\/wp\/v2\/pages\/489"}],"collection":[{"href":"https:\/\/depts.washington.edu\/cfrtc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/depts.washington.edu\/cfrtc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/cfrtc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/cfrtc\/wp-json\/wp\/v2\/comments?post=489"}],"version-history":[{"count":6,"href":"https:\/\/depts.washington.edu\/cfrtc\/wp-json\/wp\/v2\/pages\/489\/revisions"}],"predecessor-version":[{"id":2491,"href":"https:\/\/depts.washington.edu\/cfrtc\/wp-json\/wp\/v2\/pages\/489\/revisions\/2491"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/cfrtc\/wp-json\/wp\/v2\/media?parent=489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}